Anavex Life Sciences Corp. (AVXL)Healthcare | Biotechnology | New York, United States | NasdaqGS
1.48 USD
-0.01
(-0.671%) ⇩
(Oct. 15, 2026, 4 p.m.
EDT)
After hours: 1.47 -0.01 (-0.010%) ⇩ (Oct. 15, 2026, 7:10 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 6:05 a.m. EDT
The investment case here is severely compromised by a lack of fundamental earnings power and a deteriorating operational reality. The company reports negative earnings per share and negative free cash flow, indicating it is burning cash without generating returns on assets or equity. This financial bleed is exacerbated by recent negative news regarding a withdrawal of an EU filing, which likely triggered the sharp price drop seen recently. While the stock has rallied significantly over the last year, the underlying business metrics remain broken, and the recent delinquency notification adds regulatory overhang. From a valuation perspective, the negative forward P/E confirms that the market sees no near-term profitability. The options market reflects this fear, with massive put open interest at strikes far above the current price, signaling that traders expect the stock to struggle to recover to even moderate levels. Without a proven clinical success story or a clear path to profitability, this remains a speculative trap where the balance sheet is eroding faster than the stock price can fall. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.146726 |
| AutoETS | 0.149555 |
| MSTL | 0.152198 |
| AutoTheta | 0.154546 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 0.17 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.303 |
| Excess Kurtosis | -0.97 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 137,191,328 |
| Forward P/E | -2.69 |
| Beta | 1.17 |
| Website | https://www.anavex.com |
As of Oct. 10, 2026, 6:05 a.m. EDT: Speculators are aggressively positioning for downside protection, with heavy open interest in out-of-the-money puts expiring in late 2027 and early 2028. While there is some call volume at strikes significantly above the current price, the overwhelming capital deployment is in put writing and buying, suggesting a consensus view of continued volatility and potential further declines rather than an imminent rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.8346282 |
| Address1 | 630 5th Avenue |
| Address2 | 20th Floor |
| All Time High | 31.5 |
| All Time Low | 0.6 |
| Ask | 1.9 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Daily Volume10 Day | 1,549,190 |
| Average Daily Volume3 Month | 998,656 |
| Average Volume | 998,656 |
| Average Volume10Days | 1,549,190 |
| Beta | 1.174 |
| Bid | 1.09 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 1.213 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.48 |
| Current Ratio | 15.619 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.54 |
| Day Low | 1.47 |
| Display Name | Anavex Life Sciences |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,770,643,800 |
| Earnings Call Timestamp Start | 1,770,643,800 |
| Earnings Timestamp | 1,787,661,000 |
| Earnings Timestamp End | 1,795,523,400 |
| Earnings Timestamp Start | 1,795,523,400 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 18,865,326 |
| Eps Forward | -0.55 |
| Eps Trailing Twelve Months | -0.14 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.6173 |
| Fifty Day Average Change | -1.1373 |
| Fifty Day Average Change Percent | -0.43453178 |
| Fifty Two Week Change Percent | -83.46282 |
| Fifty Two Week High | 9.5 |
| Fifty Two Week High Change | -8.02 |
| Fifty Two Week High Change Percent | -0.84421057 |
| Fifty Two Week Low | 1.44 |
| Fifty Two Week Low Change | 0.03999996 |
| Fifty Two Week Low Change Percent | 0.02777775 |
| Fifty Two Week Range | 1.44 - 9.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,154,525,400,000 |
| Float Shares | 89,808,408 |
| Forward Eps | -0.55 |
| Forward P E | -2.6909091 |
| Free Cashflow | -27,060,250 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 34 |
| Fullday Change | -0.01999998 |
| Fullday Change Percent | -1.3422806 |
| Fullday Price | 1.47 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01706 |
| Held Percent Institutions | 0.40495998 |
| Implied Shares Outstanding | 92,696,842 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,759,190,400 |
| Last Split Date | 1,444,176,000 |
| Last Split Factor | 1:4 |
| Long Business Summary | Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, as well as exhibits anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71 that targets SIGMAR1 and M1 muscarinic receptors, which is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, such as cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York. |
| Long Name | Anavex Life Sciences Corp. |
| Market | us_market |
| Market Cap | 137,191,328 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_13580387 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -13,022,000 |
| Next Fiscal Year End | 1,790,726,400 |
| Non Diluted Market Cap | 217,374,094 |
| Open | 1.5 |
| Operating Cashflow | -29,291,000 |
| Operating Margins | 0.0 |
| Overall Risk | 4 |
| Phone | 844 689 3939 |
| Post Market Change | -0.00999999 |
| Post Market Change Percent | -0.67567503 |
| Post Market Price | 1.47 |
| Post Market Time | 1,792,105,831 |
| Previous Close | 1.49 |
| Price Hint | 4 |
| Price To Book | 1.2201154 |
| Profit Margins | 0.0 |
| Quick Ratio | 15.512 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.00999999 |
| Regular Market Change Percent | -0.6711403 |
| Regular Market Day High | 1.54 |
| Regular Market Day Low | 1.47 |
| Regular Market Day Range | 1.47 - 1.54 |
| Regular Market Open | 1.5 |
| Regular Market Previous Close | 1.49 |
| Regular Market Price | 1.48 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 1,695,080 |
| Return On Assets | -0.09696999 |
| Return On Equity | -0.12804 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 92,696,842 |
| Shares Percent Shares Out | 0.1464 |
| Shares Short | 13,566,524 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 13,898,140 |
| Short Name | Anavex Life Sciences Corp. |
| Short Percent Of Float | 0.1489 |
| Short Ratio | 16.63 |
| Source Interval | 15 |
| State | NY |
| Symbol | AVXL |
| Total Cash | 118,326,000 |
| Total Cash Per Share | 1.276 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.14 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.25825 |
| Two Hundred Day Average Change | -1.77825 |
| Two Hundred Day Average Change Percent | -0.54576844 |
| Type Disp | Equity |
| Volume | 1,695,080 |
| Website | https://www.anavex.com |
| Zip | 10,111 |